CoChat

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

Zhang, Mei, Zhang, Lin, Wu, Bin, Song, Haolan, An, Zhenmei, Li, Shuangqing · 2014 · Diabetes/Metabolism Research and Reviews
Cited by 127

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Context: Type 2 diabetes has reached epidemic proportions and places a heavy burden on society. Dapagliflozin is a novel treatment choice for type 2 diabetes. Objective: A meta‐analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of dapagliflozin treatment. Data Sources: Medline (via PubMed), Embase (via OVID) and the Cochrane Library (up to August 2012) were searched, and RCTs were collected. Study Selection: Studies included type 2 diabetic subjects, who had been treated with dapagliflozin, and recorded HbA 1c as outcomes. Data Extraction: Two reviewers independently assessed articles and study quality. Patient characteristics, interventions and outcomes were collected. Data Synthesis: Ten RCTs were included. Risk of bias for outcomes was low. Fixed or random effects models were used to pool the results. Dapagliflozin treatment was associated with a reduction in HbA 1c [weighted mean difference (WMD): –0.53%; 95% confidence interval (CI): −0.58% to −0.47%; p < 0.00001], fasting plasma glucose (WMD: −1.06 mmol/L; 95% CI: −1.20, −0.92; p < 0.00001), and body weight (WMD: −1.63 kg; 95% CI: −1.83, −1.43; p < 0.00001). Dapagliflozin monotherapy did not lead to hypoglycaemia [relative risk (RR): 1.44; 95% CI: 0. 86, 2.41; p = 0.17], although hypoglycaemic risk increased (RR: 1.16; 95% CI: 1.05, 1.29; p = 0.005) when dapagliflozin was combined with other hypoglycaemic drugs. Dapagliflozin increased urinary glucose excretion (WMD: 26.98; 95% CI: 21.72, 32.24; p < 0.00001) and was associated with an increased risk of urinary tract infections (RR: 1.33; 95% CI: 1.10, 1.60; p = 0.004) and genital tract infections (RR: 3.23; 95% CI: 2.50, 4.18; p = 0.00001). Conclusions: Dapagliflozin appears to be an effective treatment for type 2 diabetes, although it may increase the risk of urinary tract infections and genital tract infections. Copyright © 2013 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.2479

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 127

Metadata

Authors
Zhang, M., Zhang, L., Wu, B., Song, H., An, Z., & Li, S.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2014-03
Volume
30
Issue
3
Pages
204-221
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1517491980
Cited by
127
References
2
FWCI
1.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.